Approved in 2020 as Nexletol, bempedoic acid as the first ATP citrate lyase inhibitor and oral non-statin therapy to meet the MACE-4 primary endpoint.
In the SOLOIST-WHF trial, risk for HF readmission and CV death were reduced by more than 50% at 30- and 90-days after hospital discharge.
Studies of cardiometabolic disease pathophysiology, prevention, and treatment make science news every day. Find 12 here, at-a-glance.
SGLT-2 inhibitors and drugs to treat HFrEF were compared for efficacy in patients with HF with LVEF ≥40%.
Data from the pivotal phase 3 FIGARO-DKD cardiovascular outcomes trial with finerenone reaffirms the agent's dual cardiorenal risk reduction benefits in T2D-associated CKD.
A 5-fold greater risk for all-cause or CVD-related death in persons diagnosed with T2D before age 40 years should be a call to action for enhanced screening, study authors state.
Physical performance scores used as a proxy for function in adults aged >65 years improved CVD risk prediction beyond traditional risk factors, study authors report.
A diagnosis of NAFLD was associated with a 50% greater risk of new-onset heart failure in a meta-analysis comprised of more than 11 million individuals.
Patients with HFpEF who significantly restrict salt consumption have increased risk for cardiovascular and HF events and HF hospitalization, according to new research.
Chronic kidney disease is underdiagnosed and undertreated across major Western countries, according to findings of the new CaReMe CKD study.